PTC299 for Treatment of Neurofibromatosis Type 2
PTC299 for Treatment of Advanced Cancer
PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
† Study has passed its completion date and status has not been verified in more than two years.